SHP2 Inhibition May Resensitize NSCLC Tumors to ALK Inhibitors [Research Watch]

Targeting SHP2 suppresses ALK inhibitor resistance caused by tyrosine kinase reactivation.

from Cancer via ola Kala on Inoreader http://ift.tt/2twHLKG
via IFTTT